OptiNose Inc Raises $55 Million to Boost XHANCE Commercialization
Company Announcements

OptiNose Inc Raises $55 Million to Boost XHANCE Commercialization

Optinose Inc (OPTN) just unveiled an announcement.

OptiNose, Inc. has initiated a Registered Direct Offering, agreeing to sell over 31 million common stock shares and nearly 24 million pre-funded warrants to investors, aiming to raise approximately $55 million. Scheduled to close on May 10, 2024, the proceeds will primarily support working capital and the commercialization of their product, XHANCE. The company has also amended an earlier agreement to facilitate this offering, which includes adjusting the exercise price of existing warrants and issuing new shares to settle amendment fees, further demonstrating their strategic financial management to bolster their market position and fund growth initiatives.

Find detailed analytics on OPTN stock on TipRanks’ Stock Analysis page.

Related Articles
GlobeNewswireExpanded Access to XHANCE with Addition to National Commercial Formularies
TheFlyOptinose announces XHANCE added to Express Scripts’ national formularies
GlobeNewswireOptinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!